Package Leaflet: Information for the User
INTELENCE 100 mg tablets
etravirine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
Contents of the pack
INTELENCE contains the active substance etravirine. INTELENCE belongs to a group of medicines to treat HIV called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
INTELENCE is a medicine used in the treatment of infection by the Human Immunodeficiency Virus (HIV). INTELENCE works by reducing the amount of HIV in the body. This improves your immune system and reduces the risk of diseases related to HIV infection.
INTELENCE is used in combination with other HIV medicines to treat adults and children from 6 years of age and older who are infected with HIV and who have already used other HIV medicines.
Your doctor will explain which combination of medicines is best for you.
Do not take INTELENCE
Warnings and precautions
Talk to your doctor or pharmacist before you start taking INTELENCE.
INTELENCE does not cure HIV infection. It is one treatment that reduces the amount of virus in the blood. While taking this medicine, you can still pass HIV to others, although effective antiviral treatment reduces the risk. Ask your doctor about the precautions needed to avoid infecting others.
Elderly patients
INTELENCE has only been used in a limited number of patients aged 65 years or older.
If you belong to this age group, discuss the use of INTELENCE with your doctor.
Weight and increased lipid and glucose levels in the blood
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly due to recovery from illness and lifestyle, and in the case of blood lipids, sometimes to HIV medicines themselves. Your doctor will monitor these changes.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue due to loss of blood supply to the bone). The duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immunosuppression, increased body mass index, among others, may be some of the risk factors for the development of this disease. Signs of osteonecrosis are joint stiffness, pain, and discomfort (especially in the hip, knee, and shoulder) and difficulty moving. If you notice any of these symptoms, please consult your doctor.
Tell your doctor about your situation
Check the following points and tell your doctor if you are in any of these situations.
Children and adolescents
Do not give this medicine to children under 6 years of age and weighing less than 16 kg because the possible benefit or risk has not been established yet.
Taking INTELENCE with other medicines
INTELENCE may interact with other medicines. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In most cases, INTELENCE can be combined with HIV medicines that belong to another group. However, there are some combinations that are not recommended. In other cases, it may be necessary to increase monitoring and/or modify the dose of the medicine. Therefore, you should always inform your doctor if you are taking other HIV medicines. It is also important that you carefully read the package leaflets that come with these medicines. Follow your doctor's instructions carefully regarding which medicines can be combined.
Do not combine INTELENCE with any of the following medicines:
If you are taking any of these products, consult your doctor.
The effects of INTELENCE or other medicines may be affectedif you take
INTELENCE with any of the following medicines. It may be necessary to change the doses of some medicines, as their therapeutic effect or side effects may be affected when combined with INTELENCE. Tell your doctor if you are taking:
Pregnancy and breastfeeding
If you are pregnant, inform your doctor immediately. Pregnant women should not take INTELENCE unless specifically indicated by their doctor.
Mothers infected with HIV should not breastfeed their child, as there is a risk that the child may become infected with HIV.
Driving and using machines
Do not drive or operate machinery if you experience drowsiness or dizziness after taking your medicines.
INTELENCE contains lactose
INTELENCE tablets contain lactose. If your doctor has told you that you have an intolerance to some sugars (lactose), talk to your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Use in adults
The recommended dose of INTELENCE is two tablets twice a day.
Take two 100 mg tablets of INTELENCE in the morning after a meal.
Take two 100 mg tablets of INTELENCE in the evening after a meal.
Use in children and adolescents from 6 years of age and weighing at least 16 kg
Your doctor will tell you the correct dose based on the child's weight.
Your doctor will inform you exactly how much INTELENCE the child should take.
Instructions for taking INTELENCE for all patients
It is important to take INTELENCE after meals. If you take INTELENCE on an empty stomach, only half of the amount of INTELENCE is absorbed. Follow your doctor's instructions about the type of meal you should take with INTELENCE.
Swallow the INTELENCE tablet(s) whole with a glass of water. Do not chew the tablet(s).
Opening the child-resistant cap
The plastic bottle has a child-resistant cap that opens as follows: Push the plastic cap down while turning it counterclockwise. Remove the cap. |
If you take more INTELENCE than you should
Inform your doctor or pharmacist immediately. The most common side effects of INTELENCE are skin rash, diarrhea, nausea, and headache (see section "4. Possible side effects").
If you forget to take INTELENCE
If you realize within 6 hours of the usual time you take INTELENCE, take the tablets as soon as possible. Always take the tablets after a meal.
Then take your next dose as you usually do. If you realize after 6 hours, skip that dose and take the next one at the usual time. Do not take a double dose to make up for forgotten doses.
If you vomit within 4 hours of taking INTELENCE, take another tablet after a meal. If you vomit more than 4 hours after taking INTELENCE, it is not necessary to take another tablet until the next scheduled dose.
Contact your doctor if you have doubts about what to do if you forget a dose or vomit.
Do not stop taking INTELENCE without talking to your doctor
HIV treatment can improve your sense of well-being. Although you feel better, do not stop taking INTELENCE or your other HIV medicines. If you do, you may increase the risk of the virus becoming resistant. Consult your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency of side effects associated with INTELENCE is shown below.
Very common side effects (may affect more than 1 in 10 people)
Your doctor will tell you how to act on your symptoms and whether you should stop taking INTELENCE;
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Side effects with frequency not known (frequency cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP. The expiry date refers to the last day of the month shown.
INTELENCE tablets should be stored in the original bottle and kept tightly closed to protect from moisture. The bottle contains 3 sachets (desiccants) to keep the tablets dry. These sachets should always be kept in the bottle and should not be swallowed.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of INTELENCE
Appearance of the Product and Package Contents
This medication is presented in the form of a white to off-white, oval-shaped tablet, with the inscription “T125” engraved on one side and “100” on the other side.
A plastic bottle with 120 tablets and 3 desiccant packets to keep the tablets dry.
Marketing Authorization Holder
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
Manufacturer
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Janssen-Cilag NV Antwerpseweg 15-17 B-2340 Beerse Tel: +32 14 64 94 11 | Lithuania UAB "JOHNSON & JOHNSON" Konstitucijos pr. 21C LT-08130 Vilnius Tel: +370 5 278 68 88 |
Bulgaria “Johnson & Johnson” EAD 4, Nikolay Haytov Str. Sofia, 1407 Tel: +359 2 489 94 00 | Luxembourg/Luxemburg Janssen-Cilag NV Antwerpseweg 15-17 B-2340 Beerse Belgium Tel: +32 14 64 94 11 |
Czech Republic Janssen-Cilag s.r.o. Walterovo náměstí 329/1 CZ-158 00 Prague 5 – Jinonice Tel: +420 227 012 227 | Hungary Janssen-Cilag Kft. Nagyenyed u. 8-14 H-1123 Budapest Tel: +36 1 884 2858 |
Denmark Janssen-Cilag A/S Bregnerødvej 133 DK-3460 Birkerød Tel: +45 45 94 82 82 | Malta AM MANGION LTD. Mangion Building, Triq Gdida fi Triq Valletta MT-Hal-Luqa LQA 6000 Tel: +356 2397 6000 |
Germany Janssen-Cilag GmbH Johnson & Johnson Platz 1 D-41470 Neuss Tel: +49 2137 955-955 | Netherlands Janssen-Cilag B.V. Graaf Engelbertlaan 75 NL-4837 DS Breda Tel: +31 76 711 1111 |
Estonia UAB "JOHNSON & JOHNSON" Estonian branch Lõõtsa 2 EE-11415 Tallinn Tel: +372 617 7410 | Norway Janssen-Cilag AS Postboks 144 NO-1325 Lysaker Tel: +47 24 12 65 00 |
Greece Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε. Λεωφόρος Ειρήνης 56 GR-151 21 Πεύκη, Αθήνα Tel: +30 210 80 90 000 | Austria Janssen-Cilag Pharma GmbH Vorgartenstraße 206B A-1020 Vienna Tel: +43 1 610 300 |
Spain Janssen-Cilag, S.A. Paseo de las Doce Estrellas, 5-7 E-28042 Madrid Tel: +34 91 722 81 00 | Poland Janssen-Cilag Polska Sp. z o.o. ul. Ilzecka 24 PL-02-135 Warsaw Tel: +48 22 237 60 00 |
France Janssen-Cilag 1, rue Camille Desmoulins, TSA 91003 F-92787 Issy Les Moulineaux, Cedex 9 Tel: 0 800 25 50 75 / +33 1 55 00 40 03 | Portugal Janssen-Cilag Farmacêutica, Lda. Lagoas Park, Edifício 9 2740-262 Porto Salvo PORTUGAL Tel: +351 214 368 600 |
Croatia Johnson & Johnson S.E. d.o.o. Oreškoviceva 6h 10010 Zagreb Tel: +385 1 6610 700 | Romania Johnson & Johnson România SRL Str. Tipografilor nr. 11-15 Cladirea S-Park, Corp B3-B4, Etaj 3 013714 Bucharest, ROMÂNIA Tel: +40 21 207 1800 |
Ireland Janssen-Cilag Ltd. 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG United Kingdom Tel: +44 1 494 567 444 | Slovenia Johnson & Johnson d.o.o. Šmartinska cesta 53 SI-1000 Ljubljana Tel: +386 1 401 18 00 |
Iceland Janssen-Cilag AB c/o Vistor hf. Hörgatúni 2 IS-210 Garðabær Tel: +354 535 7000 | Slovak Republic Johnson & Johnson s.r.o. CBC III, Karadžicova 12 SK-821 08 Bratislava Tel: +421 232 408 400 |
Italy Janssen-Cilag SpA Via M.Buonarroti, 23 I-20093 Cologno Monzese MI Tel: +39 02 2510 1 | Finland Janssen-Cilag Oy Vaisalantie/Vaisalavägen 2 FI-02130 Espoo/Esbo Tel: +358 207 531 300 |
Cyprus Βαρνάβα Χατζηπαναγή Λτδ Λεωφόρος Γιώργου Κρανιδιώτη 226 Λατσί CY-2234 Λευκωσία Tel: +357 22 207 700 | Sweden Janssen-Cilag AB Box 4042 SE-16904 Solna Tel: +46 8 626 50 00 |
Latvia UAB "JOHNSON & JOHNSON" Latvian branch Mukusalas iela 101 Riga, LV-1004 Tel: +371 678 93561 | United Kingdom Janssen-Cilag Ltd. 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG - UK Tel: +44 1 494 567 444 |
Date of the last revision of this prospectus:{MM/YYYY}
Detailed information about this medication is available on the European Medicines Agency website http://www.ema.europa.eu.